NCT05962229View on ClinicalTrials.gov

Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Nicotine DependenceNicotine Vaping
Interventions
DRUG

(S)-Nicotine

Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.

DRUG

(R)- nicotine

Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.

DRUG

Racemic nicotine

Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.

Trial Locations (1)

94110

RECRUITING

Zuckerberg San Francisco General Hospital (ZSFG), San Francisco

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of California, San Francisco

OTHER